Find and Pitch Jounalists, Get Your Story Covered

Tags: Celltrion subcutaneous infliximab inflammatory bowel disease

	Profile	Recent Articles on Subject
1	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer - 5 days ago Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond - about 2 months ago Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin - 2 months ago Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer - 8 months ago
2	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis - about 1 month ago Scottish medicines consortium approves CAR T-cell therapy for blood cancer - 2 months ago Celltrion unveils promising dose escalation results for subcutaneous infliximab - 3 months ago
3	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Sanofi advances a drug for a rare, platelet-destroying disease - about 2 months ago STAT+: Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit - 3 months ago STAT+: Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer - about 1 year ago STAT+: Bristol wins U.S. approval for lung cancer drug targeting rare genetic mutation - about 1 year ago
4	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	Sanofi advances a drug for a rare, platelet-destroying disease - about 2 months ago STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more - 6 months ago
5	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL - about 2 months ago FDA Approves Earlier Use of CAR-T Products for Myeloma - 10 months ago FDA Approves First CAR-T for Chronic Lymphocytic Leukemia - 10 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - about 1 year ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - about 1 year ago Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients - about 1 year ago Non-Covalent BTK Inhibitor Approved for CLL - about 1 year ago
6	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show - about 2 months ago Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma - 4 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 4 months ago FDA Greenlights First Engineered Cell Therapy for a Solid Tumor - 6 months ago Oncolytic Virus Shows High Response Rates in BCG-Unresponsive Bladder Cancer - about 1 year ago
7	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	FDA Investigating Blood Cancer Risk With Gene Therapy Skysona - about 2 months ago
8	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? - 4 months ago
9	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - 5 months ago
10	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: FDA approves innovative T cell immunotherapy for rare soft-tissue cancer - 6 months ago

Journalists covering Celltrion